RESUMO
Organic electrochemical transistors (OECTs) have emerged as versatile platforms for broad applications spanning from flexible and wearable integrated circuits to biomedical monitoring to neuromorphic computing. A variety of materials and tailored micro/nanostructures have recently been developed to realized stretchable OECTs, however, a solid-state OECT with high elasticity has not been demonstrated to date. Herein, we present a general platform developed for the facile generation of highly elastic all-polymer OECTs with high transconductance (up to 12.7 mS), long-term mechanical and environmental durability, and sustainability. Rapid prototyping of these devices was achieved simply by transfer printing lithium bis(trifluoromethane)sulfonimide doped poly(3,4-ethylenedioxythiophene): poly(styrene sulfonate) (PEDOT:PSS/LiTFSI) microstructures onto a resilient gelatin-based gel electrolyte, in which both depletion-mode and enhancement-mode OECTs were produced using various active channels. Remarkably, the elaborate 3D architectures of the PEDOT:PSS were engineered, and an imprinted 3D-microstructured channel/electrolyte interface combined with wrinkled electrodes provided performance that was retained (> 70%) through biaxial stretching of 100% strain and after 1000 repeated cycles of 80% strain. Furthermore, the anti-drying and degradable gelatin and the self-crosslinked PEDOT:PSS/LiTFSI jointly enabled stability during > 4 months of storage and on-demand disposal and recycling. This work thus represents a straightforward approach towards high-performance stretchable organic electronics for wearable/implantable/neuromorphic/sustainable applications.
RESUMO
A hallmark of human and experimental heart failure is deficient sarcoplasmic reticulum (SR) Ca-uptake reflecting impaired contractile function. This is at least partially attributed to dephosphorylation of phospholamban by increased protein phosphatase 1 (PP1) activity. Indeed inhibition of PP1 by transgenic overexpression or gene-transfer of constitutively active inhibitor-1 improved Ca-cycling, preserved function and decreased fibrosis in small and large animal models of heart failure, suggesting that inhibitor-1 may represent a potential therapeutic target. We recently identified a novel human polymorphism (G109E) in the inhibitor-1 gene with a frequency of 7% in either normal or heart failure patients. Transgenic mice, harboring cardiac-specific expression of G109E inhibitor-1, exhibited decreases in contractility, Ca-kinetics and SR Ca-load. These depressive effects were relieved by isoproterenol stimulation. Furthermore, stress conditions (2Hz +/- Iso) induced increases in Ca-sparks, Ca-waves (60% of G109E versus 20% in wild types) and after-contractions (76% of G109E versus 23% of wild types) in mutant cardiomyocytes. Similar findings were obtained by acute expression of the G109E variant in adult cardiomyocytes in the absence or presence of endogenous inhibitor-1. The underlying mechanisms included reduced binding of mutant inhibitor-1 to PP1, increased PP1 activity, and dephosphorylation of phospholamban at Ser16 and Thr17. However, phosphorylation of the ryanodine receptor at Ser2808 was not altered while phosphorylation at Ser2814 was increased, consistent with increased activation of Ca/calmodulin-dependent protein kinase II (CaMKII), promoting aberrant SR Ca-release. Parallel in vivo studies revealed that mutant mice developed ventricular ectopy and complex ventricular arrhythmias (including bigeminy, trigeminy and ventricular tachycardia), when challenged with isoproterenol. Inhibition of CaMKII activity by KN-93 prevented the increased propensity to arrhythmias. These findings suggest that the human G109E inhibitor-1 variant impairs SR Ca-cycling and promotes arrhythmogenesis under stress conditions, which may present an additional insult in the compromised function of heart failure carriers.